Kristina Jankovic, MD· @JankovicK · X·· 16 小时前评分60
正文 · 原文
@OncoAlert 🚨 4Sights Abstracts to be presented at #ESMO26 🇪🇸 | #evERA: Promising biomarker insights after CDK4/6i! In patients with ER+/HER2- advanced #BreastCancer in the post CDK 4/6i setting giredestrant + everolimus demonstrated greater PFS benefit 🆚 SOC endocrine therapy + everolimus, regardless of ctDNA tumor fraction, with benefit observed across ESR1 variants and poor-prognosis molecular subgroups 👇
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT05113251NCT05113251按 - **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer 对上
- **标题 / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer读摘要原文 →来源：Kristina Jankovic, MD · x.com